ABSTRACT # 871: HCV Reinfection and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Patients on Opioid Agonist Therapy: Co-STAR Part B – Three Year Follow-up Study—G. Dore, at al.
The Co-STAR study is an on-going study that included patients who were on opioid agonist therapy (OAT) for at least three months to treat addiction before entering the study. There were 301 patients (genotypes 1, 4 and 6). Part A found that the overall cure rates were 91%.
This report is on Part B: a 3-year observational follow-up study to look at the re-infection rate. There were 199 participants enrolled in the follow-up phase. Every six months the participants were given drug urine screen, an HCV RNA (viral load test) to check for reinfection and a questionnaire to self-report drug use.
Conclusions: There was drug use during the follow-up period. However, of the 199 patients enrolled in the 3-year follow-up, there were ten people who were re-infected. Interestingly, of the ten people who had become re-infected three people had resolved the acute infection and two people had been re-treated. No information was given if the two people who were re-treated had achieved a cure.
Editorial Comments: These are excellent results. Personally, I am thrilled with the outcome of the trial. I think this study demonstrates that treating people with addictions can produce high cure rates and low reinfection rates.
To read the entire newsletter, click here
Alan Franciscus is the Executive Director of the Hepatitis C Support Project and the Editor-in-Chief of the HCV Advocate WebsiteShare This Page